Who Owns Galenica Company?

Galenica Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Galenica?

The ownership structure of a company is a key factor influencing its strategic decisions and operational focus. Galenica's journey, particularly its demerger from the Galenica Group and the subsequent initial public offering of Galenica Santé in April 2017, significantly altered its ownership framework. This pivotal event established Galenica Santé as an independent entity, now operating under the name Galenica and listed on the SIX Swiss Exchange under the ticker GALE.

Galenica, originally established in 1927 by sixteen Swiss French-speaking pharmacists as Collaboration Pharmaceutique S.A., began as a cooperative for central purchasing. Headquartered in Bern, Switzerland, the company expanded its operations beyond pharmaceutical distribution to become a leading integrated healthcare provider within Switzerland. Today, Galenica manages a substantial network of pharmacies, including well-known names like Amavita, Coop Vitality, and Sun Store. It also plays a crucial role in wholesale distribution, supplying pharmacies, medical practices, and hospitals, and develops its own range of health and beauty products, showcasing its extensive market presence.

In 2024, Galenica reported consolidated net sales of CHF 3,921.1 million, marking a 4.7% increase and reinforcing its strong position in the Swiss healthcare market. As a publicly traded company, its ownership is distributed among a wide array of private and institutional investors. Understanding the evolution of Galenica's ownership, from its foundational stakeholders to its current major institutional investors and public shareholders, provides insight into its governance and strategic direction. The company's history of ownership changes is a testament to its growth and adaptation in the healthcare sector, including its strategic moves like the development of its Galenica BCG Matrix.

The origins of the company trace back to 1927 when it was established as Collaboration Pharmaceutique S.A. by a group of 16 pharmacists from the French-speaking part of Switzerland. Their initial objective was to create a collaborative purchasing center, a cooperative model designed to centralize pharmaceutical procurement. While the precise equity distribution among these founders is not publicly documented, the structure was inherently designed for shared ownership to facilitate their common goal.

In 1932, the company relocated its headquarters to Bern and was renamed Galenica AG, marking its expansion beyond its initial regional focus. The company began to diversify its operations early on, establishing a scientific documentation service in 1938, which laid the groundwork for its future information management business. Following World War II, Galenica primarily focused on distribution, gradually introducing and distributing foreign pharmaceutical products within the Swiss market.

Founding Year

The company was founded in 1927.

Founders

Founded by 16 Swiss French-speaking pharmacists.

Initial Name

Initially established as Collaboration Pharmaceutique S.A.

Headquarters Relocation

Moved headquarters to Bern in 1932.

Name Change

Renamed Galenica AG in 1932.

Early Diversification

Established a scientific documentation service in 1938.

Evolution of Ownership

The company's ownership structure evolved significantly over its early years. In 1979, Galenica launched its first public offering of participation shares. This strategic move enabled the company to pursue new operational areas through acquisitions. However, control largely remained with the original base of pharmacist shareholders. This period saw a gradual expansion and diversification, transitioning from a closely held cooperative to a structure that began to incorporate broader participation, while existing shareholders maintained substantial control, influencing the Target Market of Galenica.

• The initial ownership was a cooperative model among 16 pharmacists.
• Control remained with the founding pharmacist shareholders for a significant period.
• A public offering of participation shares occurred in 1979.
• This offering facilitated expansion through acquisitions.

Galenica SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership journey of Galenica has been marked by significant strategic realignments and public market integrations. Initially offering participation shares in 1979, the company underwent a more substantial public offering in 1994, which included the conversion of some participation shares for listing on the Swiss stock exchange. This period also saw the company adopt the name Galenica Holding. A pivotal moment arrived in 1999 with a strategic alliance with Alliance Boots, a British-Swiss health group, which acquired a 20% stake in Galenica. This collaboration facilitated Alliance's entry into the Swiss market and provided Galenica with a foundation for international expansion. Following Alliance Boots' acquisition by a consortium including KKR and Stefano Pessina in 2007, Galenica shares were held by Alliance Boots Investments 2 GmbH. This ownership structure evolved again in August 2014 when Walgreens acquired Alliance Boots, forming Walgreens Boots Alliance, though the Galenica shares remained under the control of KKR and Pessina through Sprint Investments 2 GmbH.

The most transformative event in Galenica's ownership structure occurred in April 2017 with the demerger of the former Galenica Group into two distinct publicly traded entities: Vifor Pharma Group and Galenica Santé, which was subsequently renamed Galenica. Galenica Santé's Initial Public Offering (IPO) on the SIX Swiss Exchange on April 7, 2017, was priced at CHF 39.00 per share, establishing a market capitalization of CHF 1,950 million. The IPO was met with strong demand, being oversubscribed multiple times, with 97.5% of ordinary registered shares placed, indicating a substantial public float. As of December 31, 2024, Galenica reported having 20,159 shareholders. Key stakeholders holding 3% or more of the voting rights included UBS Fund Management (Switzerland) AG with 11.0%, Alecta Pensionsförsäkring holding 4.0%, BlackRock, Inc. with 3.2%, and Swisscanto Fondsleitung AG at 3.1%. This transition from a more concentrated ownership to a widely dispersed public ownership has significantly broadened the shareholder base and heightened public accountability, reinforcing governance practices towards enhanced transparency and investor engagement.

The current ownership structure of Galenica is characterized by a broad public float, a direct result of its 2017 demerger and subsequent IPO. This shift has democratized Galenica's ownership, moving away from concentrated holdings by former strategic partners to a diversified base of individual and institutional investors. Understanding who owns Galenica today involves looking at the major institutional shareholders that collectively manage significant portions of the company's stock, reflecting a commitment to its long-term strategy and Mission, Vision & Core Values of Galenica.

Galenica's Major Stakeholders (as of Dec 31, 2024)

Galenica's ownership is distributed among a large number of shareholders, with significant stakes held by institutional investors.

• UBS Fund Management (Switzerland) AG: 11.0%
• Alecta Pensionsförsäkring: 4.0%
• BlackRock, Inc.: 3.2%
• Swisscanto Fondsleitung AG: 3.1%
• Total number of shareholders: 20,159

Galenica PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of the close of 2024, the Board of Directors for the company comprised six members. This number was set to increase to seven with the proposed election of Nadine Balkanyi-Nordmann at the Annual General Meeting scheduled for April 10, 2025. This addition follows the passing of Andreas Walde. The Board holds the responsibility for the overall management and ultimate oversight of the Group, including the establishment of strategic objectives and ensuring robust corporate governance practices.

The current composition of the Board includes Dr. Markus R. Neuhaus serving as Chairman, Pascale Bruderer as Vice-Chairwoman, and members Bertrand Jungo, Judith Meier, Solange Peters, and Jörg Zulauf. The inclusion of Nadine Balkanyi-Nordmann, a new nominee, brings a range of diverse experiences and backgrounds to the board. Several members also hold other significant board positions, which can signify their independence or extensive business acumen. The company's Articles of Association permit the Board of Directors to have between five and nine members, providing flexibility in its structure.

The voting power within the company is structured such that each registered share with voting rights entitles its holder to one vote. However, a critical limitation is in place: no single shareholder can directly or indirectly control more than 5% of the share capital registered in the Commercial Register. This cap includes shares held by the shareholder and those they represent. This 5% voting threshold is designed to prevent any one entity from accumulating disproportionate influence. The Board of Directors also possesses the authority to grant voting rights up to a maximum of 20% of the share capital to strategic partners, though this power was not utilized in 2024. Public records do not indicate any recent proxy contests or activist campaigns that have significantly impacted the company's decision-making processes, suggesting a stable governance framework under the existing regulations. Understanding this structure is key to comprehending Competitors Landscape of Galenica and the broader Galenica ownership.

Galenica's Voting Power Dynamics

The voting structure is designed to distribute influence broadly among shareholders. A key restriction limits individual voting power to 5% of the share capital.

• Each registered share with voting rights equals one vote.
• No shareholder can control over 5% of the share capital.
• This cap applies to direct and indirect holdings.
• The Board can grant up to 20% voting rights to strategic partners, but this was not exercised in 2024.

Galenica Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In the period spanning 2022 to 2025, Galenica has navigated a dynamic landscape, marked by strategic expansions and shifts in its ownership profile. The company's financial performance has been robust, with sales growth of 4.7% reaching CHF 3,921.1 million in the 2024 financial year. This growth rate outpaced the market, indicating an increase in market share across its key business segments. Concurrently, adjusted EBIT saw a significant rise of 10.3%, totaling CHF 211.0 million.

These developments are intrinsically linked to the company's ownership trends, particularly through strategic investments. A notable move was the increase in Galenica's stake in Redcare Pharmacy, a collaboration that commenced in April 2023. This action underscores a broader industry trend towards strategic alliances and potential consolidation within the healthcare retail sector, influencing the overall Galenica ownership structure. The company reaffirmed its earnings guidance for 2025 in May 2025, projecting sales growth between 3-5%. Furthermore, the Annual General Meeting on April 10, 2025, approved a dividend increase of 4.5% to CHF 2.30 per share for the 2024 financial year, signaling a commitment to enhancing shareholder value and attracting investment.

Leadership transitions have also played a role in shaping the company's strategic direction and, by extension, its ownership dynamics. Felix Burkhard, the former CFO, departed at the end of 2024, with Julian Fiessinger assuming the CFO role from January 1, 2025. Additionally, Stephan Mignot joined the Executive Committee as Head of Marketing for Pharmacies on September 1, 2024, reinforcing the company's customer-centric approach. These leadership changes are indicative of ongoing strategic adjustments aimed at maintaining market leadership and adapting to the evolving healthcare landscape. The shareholder base reflects an increasing trend of institutional ownership, with major institutional investors holding substantial stakes as of December 31, 2024, which is a key aspect of Galenica AG stock ownership.

Galenica's Strategic Investments and Partnerships

Galenica's increased stake in Redcare Pharmacy exemplifies its strategy of strengthening key collaborations. This move is crucial for its market position and influences its overall ownership structure. These partnerships are vital for its continued growth and market share expansion.

Shareholder Returns and Financial Outlook

The company's commitment to shareholder returns is evident in the dividend increase for the 2024 financial year. The confirmed earnings guidance for 2025 indicates a positive outlook for Galenica AG stock ownership. This financial stability is attractive to both existing and potential Galenica shareholders.

Leadership Evolution and Market Adaptation

Recent leadership changes, including the new CFO and Head of Marketing, signal strategic adjustments within Galenica. These changes are designed to enhance customer focus and maintain market leadership. Such internal shifts are important for understanding the company's future direction and its Growth Strategy of Galenica.

Institutional Ownership Trends

The increasing presence of institutional investors in Galenica's shareholder base highlights growing confidence in the company. This trend is a significant factor in the current Galenica ownership landscape. Understanding who owns Galenica involves recognizing the influence of these major stakeholders.

Galenica Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔